Charles River Laboratories International, Inc. $CRL Holdings Raised by Madison Asset Management LLC

Madison Asset Management LLC grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 26.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,622 shares of the medical research company’s stock after acquiring an additional 3,256 shares during the quarter. Madison Asset Management LLC’s holdings in Charles River Laboratories International were worth $3,116,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Charles River Laboratories International by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock valued at $1,174,374,000 after acquiring an additional 47,432 shares during the last quarter. Invesco Ltd. boosted its position in Charles River Laboratories International by 1.0% during the 3rd quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock valued at $195,446,000 after purchasing an additional 12,035 shares during the period. Bank of America Corp DE boosted its position in Charles River Laboratories International by 13.4% during the 3rd quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock valued at $182,017,000 after purchasing an additional 137,335 shares during the period. Dimensional Fund Advisors LP increased its position in Charles River Laboratories International by 11.9% in the third quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company’s stock worth $176,909,000 after buying an additional 120,207 shares during the period. Finally, Earnest Partners LLC lifted its stake in Charles River Laboratories International by 0.8% in the third quarter. Earnest Partners LLC now owns 1,006,724 shares of the medical research company’s stock valued at $157,512,000 after buying an additional 8,467 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Down 3.6%

Shares of CRL stock opened at $162.60 on Thursday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a 1 year low of $132.58 and a 1 year high of $228.88. The stock has a fifty day moving average of $170.35 and a two-hundred day moving average of $182.83. The firm has a market capitalization of $7.83 billion, a PE ratio of -43.24, a price-to-earnings-growth ratio of 1.93 and a beta of 1.44.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. During the same quarter in the previous year, the firm posted $2.34 EPS. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 11.04 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. cut their target price on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a research note on Friday, May 8th. Citigroup raised their target price on Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 16th. UBS Group raised their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Finally, Evercore reiterated an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $205.86.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.